AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04078009 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Grazax
Description: To compare the clinical allergic response after direct installation of an aqueous solution of Aquagen Timothy Grass pollen extract via nasal allergen challenge with the clinical allergic response after direct installation of an aqueous solution of Grazax Timothy Grass lyophilisate tablets via nasal allergen challenge in grass pollen allergic individuals.
Study NCT02354768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Effects of lanreotide with current anti-diarrheal treatments (diosmectite and loperamide)
Study NCT02354768 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Effects of current anti-diarrheal treatments (diosmectite and loperamide) alone
Study NCT03025321 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial Direct Current Stimulation (tDCS)
Description: tDCS is an electrical brain stimulation method Participants will receive real-tDCS or sham twice daily for 13 min with an interval of 20 min for five consecutive days.
Study NCT03025321 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial Direct Current Stimulation (tDCS)
Description: tDCS is an electrical brain stimulation method Participants will receive real-tDCS or sham twice daily for 13 min with an interval of 20 min for five consecutive days.
Study NCT03415152 — intervention group
Intervention type: DRUG
Intervention: Omacor (Omega-3-acid ethyl esters)
Description: Observational study without intervention, Omacor is prescribed in routine manner in accordance with clinical practice and the valid Instruction for Medical Use regarding the dose, duration of therapy, patient population, and therapeutic indication.
Study NCT03614104 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Mobile Health Technology (short message service)
Description: Health education through mobile technology with Short Message Service (SMS)
Study NCT03614104 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mobile Health Technology (short message service)
Description: Health education through mobile technology with Short Message Service (SMS)
Study NCT01441869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Onglyza (saxagliptin)
Description: Oral tablets, 5 mg , single dose
Study NCT01441869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diabex
Description: Extended release oral tablets, 1000 mg, single dose
Study NCT01441869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-mg saxagliptin/1000 mg metformin
Description: Extended release fixed dose combination tablet, single dose
Study NCT01441869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diabex
Description: Extended release oral tablets, 500 mg, single dose
Study NCT01441869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-mg saxagliptin/500 mg metformin
Description: Extended release fixed dose combination tablet, single dose
Study NCT00889629 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxercalciferol
Description: Active group receives doxercalciferol (Hectorol) 1mcg
Study NCT00889629 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Group 2 receives placebo (dummy bottle with pills resembling doxercalciferol)
Study NCT00889629 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 25-OH Vitamin D3
Description: All groups received cholecalciferol
Study NCT00889629 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 25-OH Vitamin D3
Description: All groups received cholecalciferol
Study NCT04591639 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Dapagliflozin 10 milligrams [Farxiga]
Description: Patients with heart failure with or without type 2 diabetes will be either randomised to 10mg Dapagliflozin once daily or matched placebo.
Study NCT04591639 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Patients with heart failure with or without type 2 diabetes will be either randomised to 10mg Dapagliflozin once daily or matched placebo.
Study NCT01095172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375mg/m\^2, single dose given 2-4 weeks prior to transplantation
Study NCT01095172 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: dose calculated to give levels of 3-7ng/ml
Study NCT01095172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: dose calculated to give levels of 3-7ng/ml
Study NCT01095172 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenylate mofetil
Description: Mycophenylate mofetil 2g/day in divided doses
Study NCT01095172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenylate mofetil
Description: Mycophenylate mofetil 2g/day in divided doses
Study NCT01095172 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone
Description: 100mg hydrocortisone on the evening of the day of surgery and 2 further doses of hydrocortisone on day 1 post transplant.
Study NCT01095172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: 100mg hydrocortisone on the evening of the day of surgery and 2 further doses of hydrocortisone on day 1 post transplant.
Study NCT01095172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Prednisolone 0.3mg/kg on day 2, 0.25mg/kg on day 3, 0.2mg/kg on day 4 and 0.16mg/kg on day 5. On day 6 they will receive 5mg prednisolone, and on day 7 none.
Study NCT01095172 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: Reducing dose of prednisolone over at least 6 months. Subsequent steroid maintenance or withdrawal will be at the discretion of the patient's clinician.
Study NCT01738945 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Amlodipine
Description: 10 mg/day for 12 weeks
Study NCT03163446 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CF-301
Description: CF-301, 0.25 mg/kg, given as a single 2 hour iv infusion
Study NCT03163446 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, given as a single 2 hour iv infusion
Study NCT02611882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ga-68 labeled HBED-CC PSMA
Description: The imaging agent (Ga-68 HBED-CC PSMA) will be administered on an outpatient basis. It will be administered a single time intravenously prior to the PET/CT imaging. The one-time nominal injected dose will be 3 to 7 millicurie (mCi) containing 10 - 25 μg Ga-68 HBED-CC PSMA.
Study NCT02611882 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography (PET) image combined with Computed Tomography (CT) (PET/CT)
Description: Patient shall begin imaging between 55 and 70 minutes after the injection of the radiopharmaceutical. A PET/CT scan includes two parts: a PET scan and a CT scan. The CT portion of the scan produces a 3-D image that shows a patient's anatomy. The PET scan demonstrates function and what's occurring on a cellular level. The PET scan is unique because it images the radiation emitted from the patient while the CT records anatomical x-rays, showing the same area from another perspective
Study NCT02611882 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography (PET) image combined with Magnetic Resonance Imaging (MRI) (PET/MRI)
Description: Patient shall begin imaging between 55 and 70 minutes after the injection of the radiopharmaceutical. A PET/MRI scan is a two-in-one test that combines images from a positron emission tomography (PET) scan and a magnetic resonance imaging (MRI) scan. Coverage for the scan will extend from the patients vertex through the mid thighs. We will use 4 minute acquisitions per bed position for PET imaging.
Study NCT00002551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: See arm assignments.
Study NCT00002551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: See arm assignments.
Study NCT06064539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemfibrozil
Description: Tablet, taken orally
Study NCT00002551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levamisole hydrochloride
Description: See arm assignments.
Study NCT00002551 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: See arm assignments.
Study NCT04787367 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TAP block
Description: An 18-gauge needle will be introduced externally at the center of the mid axillary line between the lower costal margin and the iliac crest until the surgeon feels a pop, after which the surgeon will inject the first 2 mL of 0.25% bupivicaine to verify the correct position. Doyle's internal bulge sign (the bulge seen when the transversus abdominis muscle and peritoneum is pushed internally) will be visualized and the remainder of the 60 mL of 0.25% bupivacaine will be injected. The contralateral block will be performed according to the same technique but with only 30 ml of bupivicaine.
Study NCT01251952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denileukin Diftitox (Ontak)
Description: After receiving their stem cell transplant on Day 0, participants will receive study agent via a 30 minute infusion. Participants will also receive a 30 minute infusion of study agent on Day 21.~Follow-up visits for clinical assessment, blood draws for routine clinical laboratory studies and for immuno-correlative studies will also take place on days 42, 90, 180 and 360.
Study NCT04779424 — intervention group
Intervention type: OTHER
Intervention: POCT
Description: Capillary blood sample antibody point of care test
Study NCT00379834 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cosopt
Description: Cosopt twice daily in both eyes
Study NCT00648180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline Monohydrate Tablets 100 mg
Description: 100mg, single dose fed
Study NCT00648180 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adoxa Tablets 100 mg
Description: 100mg, single dose fed
Study NCT03884881 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: metagenomic next generation sequencing
Description: Pathogens in the NGS group will be tested by NGS，then according the NGS results, adjust antibiotics
Study NCT03884881 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Conventional pathogen detection
Description: Morphological detection, microbial culture, nucleic acid amplification technology, serological pathogen antibody titer detection and specific pathogen PCR detection. Then, according to the pathogen results, adjust antibiotics
Study NCT03884881 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Meropenem，Imipenem，Caspofene，Osstat
Description: Meropenem，Imipenem，Caspofene，Osstat
Study NCT01595373 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acyl ghrelin
Description: Acyl ghrelin 12.5 pg/min infused continuously for 300 minutes
Study NCT01595373 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Ringer acetate)
Description: Ringer acetate 2 microliter/min for 300 minutes
Study NCT02935556 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: database and epigenetic study
Study NCT01336725 — intervention group
Intervention type: BEHAVIORAL
Intervention: Teaching life style changes
Description: Single group: Teaching, group sessions, physical activity
Study NCT01336725 — intervention group
Intervention type: OTHER
Intervention: Active participation
Description: Obesity group attend 10 group sessions,are informed about and discuss needed life style changes such as weight loss and participate in physical activity and cooking.
Study NCT01336725 — intervention group
Intervention type: OTHER
Intervention: Teaching
Description: Morbid obesity group attend 40 hours of group sessions
Study NCT00230035 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leukapheresis
Study NCT00230035 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-myeloablative high dose immunosuppressive therapy conditioning (HDIT)
Study NCT00230035 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous CD34+HPC transplantation (HSCT)
Study NCT00230035 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Plasmapheresis
Study NCT00230035 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rabbit anti-thymocyte globulin
Study NCT00230035 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Study NCT00230035 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Growth colony stimulating factor (G-CSF)
Study NCT00230035 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroids
Study NCT00230035 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate mofetil
Study NCT00230035 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azathioprine
Study NCT00230035 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous immunoglobulin
Study NCT00230035 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Study NCT00230035 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Study NCT00230035 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leflunomide
Study NCT01001429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine infusion
Description: bolus of 0.5ug/kg intravenously over a period of 10-15 minutes, followed by an infusion of 0.2-0.7ug/kg/hr of drug
Study NCT01001429 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: propofol 1mg/kg intravenously as a bolus followed by 25-100ug/kg/min
Study NCT04125069 — intervention group
Intervention type: PROCEDURE
Intervention: Coronary Artery Bypass Graft (CABG)
Description: Mitochondrial function will be studied on cardiac tissue collected intraoperatively at the time of placement of the ECC cannulas by the surgeon. Fragments from auricle dissection of the right atrium of the patient will be requalified as sample residues, and will be used immediately by the surgeon to measure mitochondrial respiration (measurement of oxygen consumption by oxygenation and permeability test of the external mitochondrial membrane by the addition of cytochrome C in the oxygen chamber).
Study NCT06135181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadoquatrane (BAY1747846) 0.03 mmol Gd/kg
Description: 0.03 mmol Gd/kg by intravenous injection (at 2 mL/s)
Study NCT06135181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadoquatrane (BAY1747846) 0.1 mmol Gd/kg
Description: 0.1 mmol Gd/kg by intravenous injection (at 2 mL/s)
Study NCT06135181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching placebo
Description: 0.9% sodium chloride by intravenous injection (at 2 mL/s)
Study NCT03904823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: famitinib po
Description: Patients would be treated with famitinib po combined with HS-10296 po till progression disease or withdrawal from the study.
Study NCT03904823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-10296 po
Description: Patients would be treated with famitinib po combined with HS-10296 po till progression disease or withdrawal from the study.
Study NCT01299558 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: fluticasone furoate//GW642444
Description: Single inhaled dose of FF (800mcg)/GW642444M (100mcg) Inhalation Powder administered in the morning
Study NCT01299558 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: fluticasone furoate
Description: Single IV dose of FF (250mcg)
Study NCT01299558 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: GW642444
Description: Single IV dose of GW642444 (55mcg)
Study NCT01347463 — intervention group
Intervention type: PROCEDURE
Intervention: SCM triangle - ipsilateral nipple
Description: draws the tract of the IJV using the SCM triangle head and the ipsilateral nipple
Study NCT00643760 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study NCT00643760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GEn 1200mg/day
Description: gabapentin enacarbil 1200mg/day
Study NCT00643760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GEn 2400mg/day
Description: gabapentin enacarbil 2400mg/day
Study NCT00643760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GEn 3600mg/day
Description: gabapentin enacarbil 3600mg/day
Study NCT00643760 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Pregabalin
Description: pregabalin 300mg/day
Study NCT04600869 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Naturalistic Decision-Making Model-based Oncofertility Care Education
Description: We designed the education program according to Klein's NDM model, which explored the reasoning mechanism behind decision-making (Klein, 1993). It depends on the on-the-job training date in each unit. The education program consisted of the following: (1) Information accumulation: explanations of common cancer therapies related to subsequent infertility, psychological and mental change in cancer survivors with infertility, the necessity and method of early determination of fertility intention, and type of fertility preservation. (2) Sense-making: situational case sharing, emphasis on the guidance interaction between experienced and novice nurses to understand the patient's situation. (3) Decision-making: how to provide support, how to correspond, and attitudes toward people with strong fertility intention.
Study NCT04268160 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood draw to measure GPx activity
Description: Routine blood draw to measure levels of blood markers.
Study NCT04268160 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood draw to measure SOD activity
Description: Routine blood draw to measure levels of blood markers.
Study NCT04268160 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood draw to measure Lp(a) levels
Description: Routine blood draw to measure levels of blood markers.
Study NCT01053741 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Radiolabeled autologous seminal fluid
Description: Autologous lymphocytes labeled with 250 microcuries In-111 and 500 microcuries Tc-99m in seminal fluid vehicle.
Study NCT01053741 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Radiolabeled Normosol-R
Description: Autologous lymphocytes labeled with 250 microcuries In-111 and 500 microcuries Tc-99m in Normosol-R fluid vehicle.
Study NCT02244983 — intervention group
Intervention type: OTHER
Intervention: Patients History
Description: History taking and drawing of a blood sample
Study NCT05030116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Shenqu Xiaoshi oral liquid
Description: Shenqu Xiaoshi oral liquid
Study NCT05030116 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Domperidone suspension
Description: Domperidone suspension
Study NCT00619827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 300 IR grass pollen allergen extract tablet
Description: 300 IR grass pollen allergen extract tablet once daily during four months
Study NCT00619827 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Description: Placebo tablet once daily during four months
Study NCT03110107 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Specified dose on specified days
Study NCT03110107 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-986218
Description: Specified dose on specified days
Study NCT03110107 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days
Study NCT01386606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androxal (enclomiphene citrate)
Description: capsule oral~1X a day 6 weeks
Study NCT06064539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rifampicin
Description: Tablet, taken orally
Study NCT02249598 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: lactamica
Study NCT01386606 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone
Description: topical gel~1X a day 6 weeks
Study NCT01530269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C11-Sodium Acetate
Description: PET Imaging with C11-Sodium Acetate
Study NCT02112942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDX21459
Study NCT02112942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo
Study NCT01241474 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: EPAX 6000 (marine omega 3 EPA/DHA fatty acid concentrates
Description: 6 x 1g capsules per day of marine oil (contains 3g/d docosahexaenoic acid plus eicosapentaenoic acid) for a 9 month period
Study NCT01241474 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maize (corn) oil
Description: 6 x 1g capsules per day for 9 months
Study NCT04065490 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Valeda PBM treatment
Description: The Valeda Light Delivery System
Study NCT04065490 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Valeda Sham treatment
Description: The sham mode of the Valeda Light Delivery System.